We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug & Device Products
FDAnews Books Library
Events
Form 483s Database
Publications
Webinar Training Pass
eCFR and Guidances
Books
Clinical Products
Advertising
White Papers
Contact Us
About Us
COVID-19
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Jonathan Chapman
Jonathan Chapman
Products
PRODUCTS
Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Jonathan Chapman
Price:
$117.00
View
Viwit Pharmaceutical Co., Ltd.
Jonathan Chapman
Price:
$117.00
View
Shanghai Desano Bio-Pharmaceutical Co., Ltd.
Jonathan Chapman
and
Hongna Wang
Price:
$117.00
View
Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Jonathan Chapman
Price:
$117.00
View
Taizhou Kangping Medical Science and Technology Co., Ltd.
Jonathan Chapman
Price:
$117.00
View
Xiamen LP Pharmaceutical Co., Ltd.
Jonathan Chapman
Price:
$117.00
View
Hangzhou Zhongbo IndustriaL Co., Ltd.
Jonathan Chapman
Price:
$117.00
View
AstraZeneca Pharmaceuticals LP
Jonathan Chapman
and
Qin Xu
Price:
$117.00
View
Izeen Pharma, Inc.
Jonathan Chapman
and
David A. Oluwo
Price:
$117.00
View
Afton Scientific LLC
Jonathan Chapman
and
Marcus A. Ray
Price:
$117.00
View
View All Products by Jonathan Chapman
Upcoming Events
13
Jul
FDA Ad and Promo Enforcement Trends: Past, Present and Future
27
Jul
Applying the Lessons of the Pandemic to Your Upcoming Trial
28
Jul
EU-MDR’s Growing Pains: Are You Current with the Latest Developments?
02
Aug
Medical Device Cybersecurity: Understand the Latest Developments
03
Aug
Pharmaceutical Process Validation: Best Practices for Success
10
Aug
Gene & Cell Therapy Regulation: Comparability and Other New Developments
Featured Products
FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485
Selecting and Implementing Electronic Document Management Systems in the EU
Featured Stories
FDA Approves Foundation Medicine’s Companion Diagnostic for Genentech’s Rozlytrek
Novartis Pays $100 Million for Mallinckrodt’s Priority Review Voucher
FDA Approves Beyond Air’s LungFit PH for Newborn Pulmonary Hypertension
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
